Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non-small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study.
A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in non-small cell lung cancer (NSCLC) with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). We report herein two of the first three patients who presented with major gastrointestinal toxicities in the experimental arm of the trial. Pending further data, it would seem safer to administer EGFR-TKIs and chemotherapy sequentially rather than concomitantly.